ReviewDrugs & aging2012
Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.
Review in Drugs & aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02979665 (A Clinico-Pathological Study of the Structural and Functional Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinico-Pathological Study of the Structural and Functional Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study.BMC ophthalmology · 2015Trial
- Unexplained long-term increase in intraocular pressure during the treatment of macular disease with intravitreal anti-VEGF.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice.Science advances · 2025Article
- Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice.Cancers · 2024Review
- Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes.Scientific reports · 2022Article
- Si-Miao-Yong-An Decoction for Diabetic Retinopathy: A Combined Network Pharmacological andFrontiers in pharmacology · 2021Article
- Tibetan Medicines and Tibetan Prescriptions for the Treatment of Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Clinical pharmacology of intravitreal anti-VEGF drugs.Eye (London, England) · 2018Review
- Paracentesis following intravitreal drug injections in maintaining physiologic ocular perfusion pressure.International journal of ophthalmology · 2017Article
- Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection.Medical journal, Armed Forces India · 2017Article
- Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.Indian journal of ophthalmology · 2016Article
- Lutein and Zeaxanthin Isomers in Eye Health and Disease.Annual review of nutrition · 2016Review
- Regulation of signaling events involved in the pathophysiology of neovascular AMD.Molecular vision · 2016Review
- The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy.Central-European journal of immunology · 2016Review
- Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab.Clinical ophthalmology (Auckland, N.Z.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in adults over the age of 65 years. The advent of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections has revolutionized the management of exudative AMD. However, multiple case series of sustained elevated intraocular pressure (IOP) after intravitreal injections of anti-VEGF agents have been reported. Sustained elevated IOP has been reported with all anti-VEGF agents being used in ophthalmology and even in patients without any prior history of glaucoma. No clear correlations to injection frequency or patient characteristics have emerged from the multiple reports so far, but it appears that patients with pre-existing glaucoma or ocular hypertension and those receiving a greater number of injections with shorter injection intervals may be at a higher risk for developing ocular hypertension related to anti-VEGF agents. Until future studies elucidate the pathophysiology of sustained IOP following anti-VEGF injections, it is prudent to recognize the possibility of elevations in IOP in association with anti-VEGF therapy. Treating physicians should look for subtle optic nerve head changes and IOP measurements suspicious for glaucoma and have a low threshold for treating elevated IOP if the patient is likely to require multiple intravitreal anti-VEGF injections. Ocular hypertension following anti-VEGF injections appears to be amenable to anti-glaucoma treatment and every effort should be made to preserve the peripheral vision in these patients where central vision is already threatened by exudative AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.